Following positive trial data , retatrutide, a novel peptide option for treating non-insulin dependent metabolic disorder, has obtained conditional approval from Great Britain's Drug and Products Agency ( https://brianrdhq264048.livebloggs.com/48018909/retatrutide-treatment-peptide-british-green-light-and-launch